Neurosteroids: Endogenous regulators of the GABAA receptor

Nature Reviews Neuroscience

Volumn 6, Issue 7, 2005, Pages 565-575

  Belelli, Delia ^a   Lambert, Jeremy J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

17BETA 17 [BIS(1 METHYLETHYL)AMINOCARBONYL]ANDROSTANE 3,5 DIENE 3 CARBOXYLIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; 5ALPHA PREGNANE 3,20 DIONE; BICUCULLINE; DIAZEPAM; ETOMIDATE; FINASTERIDE; FLUOXETINE; GANAXOLONE; INDOMETACIN; ISOFLURANE; MEDROXYPROGESTERONE ACETATE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; NEUROSTEROID; PREGNANE DERIVATIVE; PROGESTERONE; PROPOFOL; PSYCHOTROPIC AGENT; SKF 105111; STEROID 5ALPHA REDUCTASE INHIBITOR; THIOPENTAL; UNCLASSIFIED DRUG; ZOLPIDEM; ZOLPIDEM TARTRATE;

ANALGESIC ACTIVITY; ANESTHESIA; ANIMAL CELL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; BEHAVIOR; DRUG POTENCY; DRUG RECEPTOR BINDING; HYPNOSIS; MAMMAL; MOOD; MOUSE; NEUROMODULATION; NEWBORN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEDATION; STEROIDOGENESIS; SYNAPTIC INHIBITION; TRANQUILIZING ACTIVITY;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; HUMANS; MODELS, BIOLOGICAL; MOOD DISORDERS; NEURAL INHIBITION; PREGNANES; RECEPTORS, GABA-A; SYNAPTIC TRANSMISSION;

ANIMALIA; MAMMALIA;

EID: 21744447595     PISSN: 1471003X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrn1703     Document Type: Review

References (122)

1. McEwen, B. S., Coinni, H. & Schumacher, M. Steroid effects on neuronal activity: when is the genome involved? Ciba Found Symp. 153, 3-12 (1990).
2. McEwen, B. S. Non-genomic and genomic effects of steroids on neural activity. Trends Pharmacol. Sci. 12, 141-147 (1991).
3. Cashin, M. F. & Moravek, V. The physiological action of cholesterol. Am, J. Physiol. 82, 294-298 (1927).
4. Selye, H. Anesthetics of steroid hormones. Proc. Soc. Exp. Biol. Med. 46, 116-121 (1941).
5. Selye, H. The antagonism between anesthetic steroid hormones and pentamethylentetrazol (metrazol). J. Lab. Clin. Med. 27, 1051-1053 (1942).
6. Schofield, C. N. Potentiation of inhibition by general anesthetics in neurons of the olfactory cortex in vitro. Pflugers Arch. 38, 249-255 (1980).
7. A receptor-mediated responses. The authors speculate that this property might be shared by endogenous pregnane steroids.
8. Belelli, D., Lan, N. C. & Gee, K. W. Anticonvulsant steroids and the GABA/benzodiazepine receptor-chloride ionophore complex. Neurosci. Biobehav. Rev. 14, 315-322 (1990).
9. A receptor function. Trends Pharmacol. Sci. 16, 295-303 (1995).
10. A receptor by progesterone metabolites. Proc. R Soc. Lond. B Biol. Sci. 231, 359-369 (1987). In this study, single-channel recordings show that low concentrations of certain progesterone metabolites prolong the open state of the GABA-gated ion channel and, at slightly greater concentrations, directly activate the receptor.
11. A receptor. Trends Pharmacol. Sci. 8, 224-227 (1987).
12. Shu, H.-J. et al. Slow actions of neurosteroids at GABA, receptors. J. Neurosci. 24, 6667-6675 (2004).
13. Gasior, M., Carter, R. B. & Witkin, J. M. Neuroactive steroids: potential therapeutic use in neurological and psychiatric disorders. Trends Pharmacol. Sci. 20, 107-112 (1999).
14. Rupprecht, R. Neuroactive steroids: mechanisms of action and neuropsychopharmacological properties. Psychoneuroendocrinology 28, 139-168 (2003).
15. Goodchild, C. S., Robinson, A. & Nadeson, R. Antinociceptive properties of neurosteroids IV: pilot study demonstrating the analgesic effects of alphadolone administered orally to humans. Br. J. Anaesth. 86, 528-534 (2001).
16. Purdy, R. H., Morrow, A. L., Moore, P. H. Jr. & Paul, S. M. Stress-induced elevations of γ-aminobutyric acid type A receptor-active steroids in the rat brain. Proc. Natl Acad. Sci. USA 88, 4553-4557 (1991).
17. Paul, S. M. & Purdy, R. H. Neuroactive steroids. FASEB J. 6, 2311-2322 (1992).
18. Robel, P., Scumacher, M. & Baulieu, E. E. in Neurosteroids: a New Regulatory Function in the Nervous System (eds Baulieu, E. E., Robel, P. & Schumacher, M.) 1-26 (Humana, Totowa, 1999).
19. Melcangi, R. C., Magnaghi, V., Galbiati, M. & Martini, L. in Neurosteroid and Brain Function (eds Biggio, G. & Purdy, R. H.) 146-176 (Academic, San Diego, 2001).
20. Mellon, S. H., Griffin, L. D. & Compagnons, N. A. Biosynthesis and action of neurosteroids. Brain Res. Brain Res. Rev. 37, 3-12 (2001).
21. Melon, S. H. & Griffin, L. D. Neurosteroids; biochemistry and clinical significance. Trends Endocrinol. Metab. 13, 35-43 (2002).
22. Schomacher, M. et al. Steroid hormones and neurosteroids in normal and pathological aging of the nervous system. Prog. Neurobiol. 71, 3-29 (2003).
23. A receptors: genomic and nongenomic mechanisms. Pharmacol. Ther. 101, 211-226 (2004).
24. A receptor activity in rat hippocampus. J. Neurosci. 24, 6521-6530 (2004). This paper presents electrophysiological evidence that the influence of ethanol and GHB on Inhibitory transmission might be mediated, in part, by an ability of these agents to release neurosteraids locally.
25. Barbaccia, M. L. Neurosteroidogenesis: relevance to neurosteroid actions in brain and modulation by psychotropic drugs. Crit. Rev. Neurobiol. 16, 67-74 (2004).
26. Uzunova, V. et al. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc. Natl Acad. Sci. USA 95, 3239-3244 (1998).
27. A Receptor (ed. Smith, S. S.) 143-172 (CRC, New York, 2004).
28. A Receptor (ed. Smith, S. S.) 291-304 (CRC, New York, 2004).
29. A Receptor (ed. Smith, S. S.) 305-316 (CRC, New York, 2004).
30. A receptors. Prog. Neurobiol. 71, 67-80 (2003).
31. A receptors in rat CA1 and dentate gyrus neurones. Neuropharmacology 45, 873-883 (2003).
32. A receptor δ subunit deletion prevents neurosteroid modulation of inhibitory synaptic currents in cerebellar neurons. Neuropharmacology 43, 646-650 (2002).
33. A IPSCs during development in rat hippocampal or cerebellar slices. J. Physiol. (Lond.) 521, 437-449 (1999).
34. A receptor subunit expression. Neuron 19, 1103-1114 (1997).
35. A receptors can be dynamically regulated by the activity of resident kinases and phosphatases. This mechanism is implicated in the control of the timed release of oxytocin during parturition.
36. A receptors at dentate gyrus synapses in a rat model of temporal lobe epilepsy. J. Physiol. (Lond.) 557, 473-487 (2004).
37. Grosso, S. et al. Inter-ictal and post-ictal circulating levels of allopregnanolone, an anticonvulsant metabolite of progesterone, in epileptic children. Epilepsy Res. 54, 29-34 (2003).
38. A receptors. Nature Rev. Neurosci. 6, 215-229 (2005).
39. A receptors. These extrasynaptic receptors can greatly influence neuronal excitability and might, therefore, be an important locus of neurosteroid action.
40. A receptor-mediated inhibition. J. Physiol. (Lond.) 562, 37-46 (2005).
41. Fritschy, J. M. & Brunig, I. Formation and plasticity of GABAergic synapses: physiological mechanisms and pathophysiological implications. Pharmacol. Ther. 98, 299-323 (2003).
42. Mihalek, R. M. et al. Attenuated sensitivity to neuroactive steroids in γ-aminobutyrate type A receptor δ subunit knockout mice. Proc. Natl Acad. Sci. USA 96, 12905-12910 (1999).
43. Hamann, M., Rossi, D. J. & Attwell, D. Tonic and spillover inhibition of granule cells control information flow through cerebellar cortex. Neuron 33, 625-633 (2002).
44. Poroello, D. M. et al. Intact synaptic GABAergic inhibition and altered neurosteroid modulation of thalamic relay neurons in mice lacking δ subunit. J. Neurophysiol. 89, 1378-1386 (2003).
45. Caraiscos, V. B. et al. Tonic inhibition in mouse hippocampal CA1 pyramidal neurons is mediated by α5 subunit-containing γ-aminobutyric acid type A receptors. Proc. Natl Acad. Sci. USA 101, 3662-3667 (2004).
46. A receptors. Neuropharmacology 43, 651-661 (2002).
47. A receptor subunit. Nature 385, 820-823 (1997).
48. A receptor subunit conferring atypical functional properties. J. Neurosci. 17, 5027-5037 (1997).
49. A receptor δ subunit results in insensitivity to anaesthetics. Neuropharmacology 43, 662-668 (2002).
50. A receptors. Br. J. Pharmacol. 136, 965-974 (2002).
51. A receptors containing the δ subunit. J. Neurosci. 22, 1541-1549 (2002).
52. A receptor channels from low- to high-efficacy gating patterns. J. Neurosci. 23, 10934-10943 (2003).
53. Smart, T. G., Thomas, P. Brandon, N. J. & Moss, S. J. in Pharmacology of GABA and Glycine Transmission Vol. 150 (ed. Mohler, H.) 195-226 (Springer, Berlin, 2001).
54. Moss, S. J. & Smart, T. G. Constructing inhibitory synapses. Nature Rev. Neurosci. 2, 240-250 (2001).
55. A receptors. Cell. Mol. Life Sci. 62, 119-127 (2005).
56. A receptor trafficking, channel activity, and functional plasticity of inhibitory synapses. Pharmacol. Ther. 102, 195-221 (2004).
57. Collingridge, G. L., Isaac, J. T. & Wang, Y. T. Receptor trafficking and synaptic plasticity. Nature Rev. Neurosci. 5, 952-962 (2004).
58. A receptor modulators and alcohol in mice lacking PKCε. Nature Neurosci. 2, 997-1002 (1999).
59. Hodge, C. W. et al. Decreased anxiety-like behavior, reduced stress hormones, and neurosteroid supersensitivity in mice lacking protein kinase Cε. J. Clin. Invest. 110, 1003-1010 (2002).
60. A receptor. J. Pharmacol. Exp. Ther. 280, 1284-1295 (1997).
61. A-receptor-mediated responses, which indicate the presence of a background 'neurosteroid tone'.
62. Li, X., Bertics, P. J. & Karavolas, H. J. Regional distribution of cytosolic and particulate 5α-dihydroprogesterone 3α-hydroxysteroid oxidoreductases in female rat brain. J. Steroid Biochem. Mol. Biol. 60, 311-318 (1997).
63. Mensah-Nyagan, A. G. et al. Neurosteroids: expression of steroidogenic enzymes and regulation of steroid biosynthesis in the central nervous system. Pharmacol. Rev. 51, 63-81 (1999).
64. Normington, K. & Russell, D. W. Tissue distribution and kinetic characteristics of rat steroid 5α-reductase isozymes. Evidence for distinct physiological functions. J. Biol. Chem. 267, 19543-19554 (1992).
65. A receptor agonist muscimol. These data support the concept of an endogenous neurosteroid tone.
66. A receptor function. Neuropharmacology 44, 49-55 (2003).
67. A Receptor (ed. Smith S. S.) 339-358 (CRC, New York, 2004).
68. A miniature IPSCs in lamina II of the spinal cord. J. Neurosci. 24, 907-915 (2004).
69. Schlichter, R. et al. Modulation of GABAergic synaptic transmission by the non-benzodiazepine anxiolytic etifoxine. Neuropharmacology 39, 1523-1535 (2000).
70. A receptors. Mol. Pharmacol. 65, 1191-1197 (2004). This study presents the first evidence of a neurosteroid 'antagonist', which antagonizes both the GABA-enhancing and anaesthetic actions of the 5α-pregnanes. This compound had no effect on GABA-evoked responses per se, or on the GABA-modulatory actions of barbiturates, benzodiazepines or 5β-pregnane steroids. These results further strengthen the concept of a neurosteroid binding site on the receptor protein.
71. A receptor. Furthermore, the enantioselectivity indicates a specific protein binding site for this neurosteroid.
72. A receptor modulation and anesthesia. J. Pharmacol. Exp. Ther. 293, 1009-1016 (2000).
73. Mohler, H., Batlersby, M. K. & Richards, J. G. Benzodiazepine receptor protein identified and visualized in brain tissue by a photoaffinity label. Proc. Natl Acad. Sci. USA 77, 1666-1670 (1980).
74. 3H]flunitrazepam is histidine 102 of the δ subunit. J. Biol. Chem. 271, 9209-9214 (1996).
75. 3H] muscimol photoaffinity substrate in the bovine γ-aminobutyric acidA receptor α subunit. J. Biol. Chem. 269, 20380-20387 (1994).
76. Darbandi-Tonkabon, R. et al. Photoaffinity labeling with a neuroactive steroid analogue. 6-azi-pregnanolone labels voltage-dependent anion channel-1 in rat brain. J. Biol. Chem. 278, 13196-13206 (2003).
77. A receptor modulation and anesthesia. J. Pharmacol. Exp. Ther. 308, 502-511 (2004).
78. A receptor at sites on the N-terminal side of the middle of TM2. Neuroreport 9, 379-383 (1998).
79. A receptor in anesthetic modulation and direct activation. J. Biol. Chem. 278, 42821-42828 (2003).
80. Morris, K. D., Moorefield, C. N. & Amin, J. Differential modulation of the γ-aminobutyric acid type C receptor by neuroactive steroids. Mol. Pharmacol. 56, 752-759 (1999).
81. Morris, K. D. W. & Amin, J. Insight into the mechanism of action of neuroactive steroids. Mol. Pharmacol. 66, 56-69 (2004).
82. 1 receptor. Br. J. Pharmacol. 127, 601-604 (1999).
83. A receptors via two distinct and separable mechanisms. Nature Neurosci. 3, 1274-1281 (2000).
84. Belelli, D., Pistis, I., Peters, J. A. & Lambert, J. J. General anaesthetic action at transmitter-gated inhibitory amino acid receptors. Trends Pharmacol. Sci. 20, 496-502 (1999).
85. Belelli, D. et al. The interaction of the general anesthetic etomidate with the γ-aminobutyric acid type A receptor is influenced by a single amino acid. Proc. Natl Acad. Sci. USA 94, 11031-11036 (1997).
86. Ueno, S. et al. Sites of positive allosteric modulation by neurosteroids on ionotropic faminobutyric acid receptor subunits. FEBS Lett. 566, 213-217 (2004).
87. A receptors. J. Physiol. (Lond.) 558, 59-74 (2004).
88. Paradiso, K., Zhang, J. & Steinbach, J. H. The C terminus of the human nicotinic α4β2 receptor forms a binding site required for potentiation by an estrogenic steroid. J. Neurosci. 21, 6561-6568 (2001).
89. 3δγ-aminobutyric acid type A receptors at low concentrations known to affect humans. Proc. Natl Acad. Sci. USA 100, 15218-15223 (2003).
90. A receptors in hippocampal neurons. J. Neurosci. 24, 8379-8382 (2004).
91. Tokunaga, S., McDaniel, J. R., Morrow, A. L. & Matthews, D. B. Effect of acute ethanol administration and acute allopregnanolone administration on spontaneous hippocampal pyramidal cell neural activity. Brain Res. 967, 273-280 (2003).
92. A receptors in central synapses. J Neurosci. 19, 578-588 (1999).
93. A receptor function. J. Physiol. (Lond.) 546, 641-646 (2003).
94. Colombo, G. et al. Characterization of the discriminative stimulus effects of γ-hydroxybutyric acid as a means for unraveling the neurochemical basis of γ-hydroxybutyric acid actions and its similarities to those of ethanol. Alcohol 20, 237-245 (2000).
95. Galloway, G. P. et al. γ-hydroxybutyrate: an emerging drug of abuse that causes physical dependence. Addiction 92, 89-96 (1997).
96. A receptors. Trends Pharmacol. Sci. 18, 425-429 (1997).
97. Dong, E. et al. Brain 5α-dihydroprogesterone and allopregnanolone synthesis in a mouse model of protracted social isolation. Proc. Natl Acad. Sci. USA 98, 2849-2854 (2001).
98. Guidotti, A. et al. Tne socially-isolated mouse: a model to study the putative role of allopregnanolone and 5α-dihydroprogesterone in psychiatric disorders. Brain Res. Brain Res. Rev. 37, 110-115 (2001).
99. Pinna, G., Costa, E, & Guidotti, A. Ruoxetine and norfluoxetine stereospecifically facilitate pentobarbital sedation by increasing neurosteroids. Proc. Natl Acad. Sci. USA 101, 6222-6225 (2004).
100. A receptor by depressant barbiturates and pregnane steroids. Br. J. Pharmacol. 94, 1257-1269 (1988).
101. Griffin, L. D. & Mellon, S. H. Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc. Natl Acad. Sci. USA 96, 13512-13517 (1999).
102. Trauger, J. W., Jiang, A., Stearns, B. A. & LoGrasso, P. V. Kinetics of allopregnanolone formation catalyzed by human 3α-hydroxysteroid dehydrogenase type III (AKR1C2). Biochemistry 41, 13451-13459 (2002).
103. Rosciszevska, D., Buntner, B., Guz, I. & Zawisza, L. Ovarian hormones, anticonvulsant drugs, and seizures during the menstrual cycle in women with epilepsy. J. Neurol. Neurosurg. Psychiatry 49, 47-51 (1986).
104. Herzog, A. G. & Frye, C. A. Seizure exacerbation associated with inhibition of progesterone metabolism. Ann. Neurol. 53, 390-391 (2003).
105. Reddy, D. S. Role of neurosteroids in catamenial epilepsy. Epilepsy Res. 62, 99-118 (2004).
106. Newmark, M. E. & Penry, J. K. Catamenial epilepsy: a review. Epilepsia 21, 281-300 (1980).
107. Owens, D. F. & Kriegstein, A. R. Is there more to GABA than synaptic inhibition? Nature Rev. Neurosci. 3, 715-727 (2002).
108. Ben Ari, Y. Excitatory actions of GABA during development: the nature of the nurture. Nature Rev. Neurosci. 3, 723-739 (2002).
109. Brinton, R. D. The neurosteroid 3α-hydroxy-5α-pregnan-20-one induces cytoarchitectural regression in cultured fetal hippocampal neurons. J. Neurosci. 14, 2783-2774 (1994).
110. Grobin, A. C., Heenan, E. J., Lieberman, J. A. & Morrow, A. L. Perinatal neurosteroid levels influence GABAergic interneuron localization in adult rat prefrontal cortex. J. Neurosci. 23, 1832-1839 (2003).
111. A receptor overactivation. J. Neurosci. 20, 3147-3156 (2000).
112. Griffin, L. D., Gong, W., Verot, L. & Mellon, S. H. Niemann-Pick type C disease involves disrupted neurosteroidogenesis and responds to allopregnanotone. Nature Med. 10, 704-711 (2004). This report describes a mouse model of NP-C disease, in which the neurosteroid 3α,5α-THPROG is undetectable. Remarkably, neonatal administration of this steroid delayed the appearance of neuropathology in these mice and prolonged their lifespan, which points to a possible therapy.
113. Weill-Engerer, S. et al. Neurosteroid quantification in human brain regions: comparison between Alzheimer's and nondemented patients. J. Clin. Endocrinol. Metab. 87, 5133-5143 (2002).
114. di Michele, F. et al. Decreased plasma and cerebrospinal fluid content of neuroactive steroids in Parkinson's disease. Neurol. Sci. 24, 172-173 (2003).
115. A receptor isoforms mediate the behavioural actions of benzodiazepines and certain general anaesthetics.
116. Rudolph, U. & Antkowiak, B. Molecular and neuronal substrates for general anaesthetics. Nature Rev. Neurosci. 5, 709-720 (2004).
117. A receptor isoforms. J. Neurosci. 23, 8608-8617 (2003).
118. A receptors: classification on the basis of subunit structure and receptor function. Pharmacol. Rev. 50, 291-313 (1998).
119. A receptor subtypes. Curr Top. Med. Chem. 2, 795-816 (2002).
120. A receptor genes in the human genome. J. Biol. Chem. 279, 41422-41435 (2004).
121. Minier, F. & Sigel, E. Techniques: use of concatenated subunits for the study of ligand-gated ion channels. Trends Pharmacol. Sci. 25, 499-503 (2004).
122. A circuits in brain development and therapy. Biochem. Pharmacol. 68, 1685-1690 (2004).